Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB6426 for Injection in Patients With Advanced Malignancies

NCT07730190 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07730190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07730190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB6426 for Injection in Patients With Advanced Malignancies
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 25, 2026
Completion date
May 31, 2028
Enrollment
145 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies